Literature DB >> 2558032

Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia.

H A Cubie1, M Norval, L Crawford, L Banks, T Crook.   

Abstract

The cell-mediated immune response (CMI) to E6 and E4 fusion proteins of human papillomavirus type 16 (HPV-16), E6 fusion protein of HPV-18, and to control proteins similarly produced, was analysed in 29 patients with cervical intraepithelial neoplasia (CIN) and in 15 age-matched laboratory personnel using a lymphocyte proliferation assay (LPA). Compared to controls without any added proteins, a positive response (stimulation index greater than 2.0) to the highly purified E6 control protein was found in only one patient. Positive responses to the E4 control protein which contained beta-galactosidase were noted in three patients and two controls. With control proteins as baseline, the lymphocytes from nine patients (28%) and three laboratory personnel (20%) responded to at least on HPV fusion protein after 7 days in culture. Stimulation indices were low in both groups with a range of 2.06-4.69 and the difference in incidence of positive responses between the groups is not significant. Proliferative responses to HPV-1 and HPV-2 virion antigens were noted in 6/23 (26%) of the patients and 2/15 (18%) of the other group. No correlation between responsiveness and degree of dysplasia or presence of koilocytes was found in the patient group. The relevance of the low proliferative responses is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558032      PMCID: PMC2249547          DOI: 10.1017/s0950268800031022

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  31 in total

1.  Human papilloma viruses and cancer.

Authors:  H zur Hausen; L Gissmann; W Steiner; W Dippold; I Dreger
Journal:  Bibl Haematol       Date:  1975-10

2.  Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens.

Authors:  A K Lee; M Eisinger
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

3.  Viral warts, herpes simplex and herpes zoster in patients with secondary immune deficiencies and neoplasms.

Authors:  W L Morison
Journal:  Br J Dermatol       Date:  1975-06       Impact factor: 9.302

Review 4.  Immunopathology of papillomavirus-induced warts and skin cancers in immunodepressed and immunosuppressed patients.

Authors:  M A Lutzner
Journal:  Springer Semin Immunopathol       Date:  1982

5.  The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein.

Authors:  D Smotkin; F O Wettstein
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events?

Authors:  H zur Hausen
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

7.  Identification of a second transforming region in bovine papillomavirus DNA.

Authors:  J T Schiller; W C Vass; D R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

8.  The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women.

Authors:  F Sillman; A Stanek; A Sedlis; J Rosenthal; K W Lanks; D Buchhagen; A Nicastri; J Boyce
Journal:  Am J Obstet Gynecol       Date:  1984-10-01       Impact factor: 8.661

9.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.

Authors:  L J Kinlen; A G Sheil; J Peto; R Doll
Journal:  Br Med J       Date:  1979-12-08

10.  Easy identification of cDNA clones.

Authors:  U Rüther; B Müller-Hill
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  8 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  Cancer of the cervix: prospects for immunological control.

Authors:  D H Davies; G A McIndoe; B M Chain
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

3.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

4.  T-cell response to cottontail rabbit papillomavirus structural proteins in infected rabbits.

Authors:  R Selvakumar; L A Borenstein; Y L Lin; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

6.  Leukocyte proliferation in vitro against cottontail rabbit papillomavirus in rabbits with persisting papillomas/cancer or after regression.

Authors:  R Höpfl; N D hristensen; M G Angell; J W Kreider
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

7.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

8.  New Approaches to Immunotherapy for HPV Associated Cancers.

Authors:  Anne-Sophie Bergot; Andrew Kassianos; Ian H Frazer; Deepak Mittal
Journal:  Cancers (Basel)       Date:  2011-09-02       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.